drugset
drugset / Trial / NCT04815213

The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans

NCT04815213 ↗

Phase 1 Active not recruiting 10 enrolled University of Jordan
Non-randomizedParallel-groupOpen-labelOther

Summary

Autologous bone marrow-derived mesenchymal cells will be injected into patients diagnosed with premature ovarian failure

Timeline

Start
2022-01-01
Primary completion
2025-01-31
Completion
2027-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject BM-MSCs Cell therapy 2e+07 cells Other
Subject EV Other / unclassified — —

Indications

primary ovarian failure